Roche Holding AG Basel American Depositary Shares (RHHBY)

$39.03 0.34 (0.88%)

15:53 EDT RHHBY Stock Quote Delayed 30 Minutes

Biotech Movers: Keryx Jumps, Sarepta Slips

By Kyle Woodley, Senior Investing Editor, Kiplinger Feb 4, 2013

Among last week's highlights, Keryx jumps on a solid Phase III trial, Sarepta gets pounded from a fake tweet and Halozyme suffers from analyst downgrades.

Flu Season: Where Investors Can Find Relief

Biotech Movers: A Tough Week All Around

Who Has the Best Pharma Pipeline?

Volume:

Previous Close -

Market Cap -

PE Ratio -

EPS -

Volume (Avg. Vol.) 4.97M

Day's Range $38.99 - $39.66

52-Week Range $37.88 - $53.86

Dividend & Yield N/A (N/A)

RHHBY Stock Predictions, Articles, and Roche Holding AG Basel American Depositary Shares News

From InvestorPlace
From the Web

Israel: Beyond the Risk, Opportunities Beckon

By Alyssa Oursler, InvestorPlace Contributor Aug 10, 2012

When you think of Israel, you probably think of conflict. But it has a strong economy and growing companies if you're willing to be a bit daring.

Pharma’s Q2 Earnings Lesson: The Big Picture Looks Good

By James Brumley, InvestorPlace Feature Writer Aug 2, 2012

The promising signs coming out of pharma this quarter doesn't mean you can just pick a stock out of a hat -- but it does mean a few are worth picking.

Novartis Wins Approval for Breast Cancer Drug

By Christopher Freeburn, InvestorPlace Writer Jul 23, 2012

The FDA has granted approval for Novartis' drug Afinitor to be used as a treatment for breast cancer after it showed promise in clinical trials.

Retail Results Spoil the Day — Monday’s IP Market Recap

By Marc Bastow, InvestorPlace Assistant Editor Jul 16, 2012

A disappointing retail report and mixed results for Citigroup's second quarter weighed on markets Monday, though M&A news sparked life into pharma.

Medidata Solutions a Strong Buy in Cloud Computing

By Hilary Kramer, Editor, GameChangers Jul 5, 2012

Medidata Solutions is a fast-growing cloud services provider to the health care industry that is poised for even better growth and is a buying opportunity

Nestle: A Global Dividend Powerhouse

By Dividend Growth Investor Jun 2, 2012

Nestle is a world wide brand name that produces products, earnings, and dividends at a remarkable rate every year. Nestle is a great portfolio buy.

Obesity: The Next Investment Driver

By James Brumley, InvestorPlace Feature Writer May 11, 2012

The global market for weight-control products of all types is forecast to hit $53 billion in just five years, and several companies are primed to profit.

Feel Safe Scooping Up Swiss Stocks

By Charles Sizemore, Principal of Sizemore Capital Apr 27, 2012

There's a lot to like about Switzerland as an investment haven. It's not a perfect environment, but a number of Swiss stocks look promising right now.

Cue the Biotech M&A Attack!

By Gene Marcial, InvestorPlace Contributor Apr 20, 2012

A rush of buyout activity in biotechs like Human Genome and Illumina could produce more frenzied M&A deals down the road.

3 New Biotech Buys for Your Portfolio

By Louis Navellier, Editor, Growth Investor Apr 10, 2012

Three new biotech buys lead the way for additions to your portfolio as we head into April.

Analysts Run the Apple Asylum — Tuesday’s IP Market Recap

By Kyle Woodley, Senior Investing Editor, Kiplinger Apr 3, 2012

Price targets keep climbing to the moon: $715, $910 -- even $1,001.

Here Comes a Bidding War for Amylin

By Gene Marcial, InvestorPlace Contributor Apr 2, 2012

Approval of its diabetes drug has Big Pharma banging on its door, with Bristol-Myers Squibb already said to have offered $3.5 billion, or $22 per share.

Generic Versions of Boniva Approved By the FDA

By InvestorPlace Staff Mar 20, 2012

The FDA approved the first generic versions of osteoporosis drug Boniva, allowing manufacturers like Apotex, Orchid Healthcare and Mylan to make the drug.

Breaking Down Societe Generale’s Top 40 Dividend Stocks in the World

By Kyle Woodley, Senior Investing Editor, Kiplinger Mar 14, 2012

Societe Generale recently put out its annual list of the top 40 dividend payers across the globe. Here's a look at those companies, as well as a few trends.

Why Illumina’s Future Remains Bright

By Gene Marcial, InvestorPlace Contributor Feb 17, 2012

Rejection of Roche's takeover bid has cooled ILMN shares, but many expect Roche to step up its advances. If not, Illumina still has great growth prospects.

Amylin Gets a Boost From Its Diabetes Drug Approval

By Barry Cohen, Health Care Writer Jan 31, 2012

FDA approval of Bydureon -- a once-a-week injectable drug -- could make Amylin a takeover target for a Big Pharma.

14,849% Profits in Red-Hot Penny Stocks! … Or Go Bankrupt

By Jeff Reeves Jan 26, 2012

Penny stock investment scams and over-hyped newsletters dangle the prospect of profits, but these cheap stocks are nothing but risky speculations.

Illumina Sparks Mean Gene Rally — Wednesday’s IP Market Recap

By Kyle Woodley, Senior Investing Editor, Kiplinger Jan 25, 2012

A hostile offer from Roche warms investors' hearts.

Roche’s Hostile Bid for Illumina Could Reach $60 Per Share

By Barry Cohen, Health Care Writer Jan 25, 2012

Swiss health care giant Roche made a hostile bid to buy Illumina for $44.50 per share, but many think that number will be higher when all is said and done.